GERMANTOWN, Md., Jan. 12, 2022 /PRNewswire/ -- Precigen,
Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing
in the development of innovative gene and cell therapies to improve
the lives of patients, today presented pipeline and corporate
updates at the 40th Annual J.P. Morgan Healthcare Conference.
Helen Sabzevari, PhD, President and
CEO of Precigen, presented a summary of 2021 achievements and set
forth Precigen's goals for 2022.
Precigen's presentation included the following pipeline
announcements:
PRGN-3006 UltraCAR-T in Acute Myeloid Leukemia (AML)
- Overview: PRGN-3006 is an investigational multigenic,
autologous chimeric antigen receptor T cell (CAR-T) therapy
engineered to simultaneously express a CAR specifically targeting
CD33, membrane bound IL-15 (mbIL15), and a kill switch. PRGN-3006
UltraCAR-T is under evaluation in a Phase 1/1b clinical trial for the treatment of patients
with relapsed or refractory AML or higher-risk myelodysplastic
syndromes (MDS). Trial subjects receive the PRGN-3006 infusion
either without prior lymphodepletion (Cohort 1) or following
lymphodepleting chemotherapy (Cohort 2). PRGN-3006 UltraCAR-T has
been granted Orphan Drug Designation in patients with AML by the
FDA.
- Program Updates: Precigen announced enrollment
completion for Dose Level 3 of the lymphodepletion cohort. Interim
data for patients treated in Dose Levels 1-3 of the
non-lymphodepletion cohort and Dose Levels 1-2 of the
lymphodepletion cohort were recently presented at the 63rd American
Society of Hematology (ASH) Annual Meeting and Exposition. The dose
escalation phase of the study is now complete for both the
lymphodepletion and non-lymphodepletion cohorts and the Company
plans to initiate a multicenter expansion phase of the study at
Dose Level 3 with lymphodepletion in the first half of 2022. The
Company plans to incorporate a repeat dosing regimen in the
expansion phase. Additional Phase 1/1b data is expected in 2022.
PRGN-3005 UltraCAR-T in Ovarian Cancer
- Overview: PRGN-3005 UltraCAR-T is an investigational
multigenic, autologous CAR-T cell therapy engineered to express a
CAR specifically targeting the unshed portion of MUC16, which is
highly expressed on ovarian tumors with limited normal tissue
expression, mbIL15, and a kill switch. PRGN-3005 UltraCAR-T is
under evaluation in a Phase 1/1b
clinical trial for the treatment of patients with advanced,
recurrent platinum-resistant ovarian cancer. Trial subjects receive
PRGN-3005 either via intraperitoneal (IP) (Arm A) or intravenous
(IV) (Arm B) infusion.
- Program Updates: Precigen announced enrollment
completion for Dose Level 3 of the IV arm, completing enrollment in
both the IP and IV arms in the dose escalation phase of the study.
Interim data for patients treated in Dose Levels 1-3 of the IP arm
were recently presented at the Company's 2021 R&D Virtual
Event. The Company has received FDA clearance to incorporate
lymphodepletion at Dose Level 3 of the IV arm and will initiate the
multicenter expansion phase of the study, incorporating
redosing.
PRGN-3007 Next Generation UltraCAR-T with Intrinsic PD-1
Inhibition
- Overview: PRGN-3007, based on the next generation of the
UltraCAR-T platform, is an investigational multigenic, autologous
CAR-T cell therapy engineered to simultaneously express a CAR
targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1),
mbIL15, a kill switch, and a novel mechanism for the intrinsic
blockade of PD-1 gene expression. ROR1 is aberrantly expressed in
multiple hematological tumors, including chronic lymphocytic
leukemia (CLL), mantle cell leukemia (MCL), acute lymphoblastic
leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL) and solid
tumors, including breast adenocarcinomas such as triple negative
breast cancer (TNBC), pancreatic cancer, ovarian cancer, and lung
adenocarcinoma. ROR1 is minimally expressed in healthy adult
tissues.
- Program Updates: Precigen plans to initiate dosing in
the Phase 1 study in ROR1+ hematological (CLL, MCL, ALL, DLBCL) and
solid (TNBC) tumors in 2022.
PRGN-2012
AdenoVerse™ Immunotherapy in
Recurrent Respiratory Papillomatosis (RRP)
- Overview: PRGN-2012 is an investigational off-the-shelf
(OTS) AdenoVerse immunotherapy designed to elicit immune responses
directed against cells infected with HPV 6 or HPV 11 for treatment
of RRP. PRGN-2012 is currently under evaluation in a Phase 1
clinical trial under a Cooperative Research and Development
Agreement (CRADA) with the National Cancer Institute (NCI). The
Phase 1 trial is designed to follow 3+3 dose escalation of
PRGN-2012 as an adjuvant immunotherapy following standard-of-care
surgical removal of visible papillomas in adult patients with RRP.
PRGN-2012 has been granted Orphan Drug Designation in patients with
RRP by the FDA.
- Program Updates: Precigen announced enrollment
completion for the Phase 1 dose escalation and expansion cohorts of
the Phase 1 study. Interim data for the Phase 1 study were recently
presented at the Company's 2021 R&D Virtual Event. The Company
plans to seek FDA guidance on a rapid regulatory strategy for
PRGN-2012 in RRP given the positive interim results and significant
unmet patient need. Additional Phase 1 expansion data is expected
in the second half of 2022.
PRGN-2009 AdenoVerse Immunotherapy in HPV-associated
Cancers
- Overview: PRGN-2009 is an OTS investigational
immunotherapy utilizing the AdenoVerse platform designed to
activate the immune system to recognize and target HPV-positive
(HPV+) solid tumors. PRGN-2009 is currently under evaluation in a
Phase 1/2 clinical trial under a CRADA with the NCI. The Phase 1
trial is evaluating safety and response of PRGN-2009 as a
monotherapy (Arm A) and in combination with M7824 (Arm B) in
previously treated patients with recurrent or metastatic
HPV-associated cancers.
- Program Updates: Precigen announced enrollment
completion in the Phase 1 monotherapy arm. Enrollment is ongoing in
the Phase 1 combination arm and the Phase 2 monotherapy arm in
newly diagnosed OPSCC patients. Interim data for patients in the
Phase 1 monotherapy and combination arms treated at Dose Levels 1-2
were recently presented at the Company's 2021 R&D Virtual
Event. Additional Phase 1 data for both arms is expected in 2022.
The Company plans to seek FDA guidance on a rapid regulatory
strategy for PRGN-2009 given the positive interim results and
significant unmet patient need. The Company also plans to initiate
a Phase 2 study in advanced HPV-associated cancer indications in
combination with an approved anti-PD-1 checkpoint inhibitor.
AG019 ActoBiotics™
- Overview: AG019 is an investigational therapy designed
to induce oral immune tolerance to reverse type 1 diabetes (T1D)
and is currently under clinical evaluation for the treatment of
early-onset T1D.The Phase 1b/2a
clinical trial is evaluating AG019 as a monotherapy and in
combination with teplizumab (PRV-031), which is currently under
investigation in the PROTECT Phase 3 study for the treatment of
newly diagnosed T1D.
- Program Updates: Precigen announced the completion of
the Phase 1b/2a clinical trial.
Positive results from the trial were presented last year at the
Federation of Clinical Immunology Societies (FOCIS) Virtual Annual
Meeting and European Association for the Study of Diabetes (EASD)
57th Annual Meeting. The Company plans to initiate discussions with
the FDA and European Medicines Agency (EMA) for Phase 2/3 clinical
trial design for AG019 in T1D.
"Precigen made significant clinical progress in 2021
across our pipeline programs. We were able to meet the major
clinical goals we outlined at JPM last year, and exceeded some
goals such as the rapid progress made for PRGN-2012 in RRP. Interim
data presented in 2021 across three platforms – UltraCAR-T,
AdenoVerse, ActoBiotics – and five clinical programs continue to
produce positive results" said Helen
Sabzevari, PhD, President and CEO of Precigen, "In 2022, we
will continue to advance our clinical programs with a concentration
on rapid paths to licensure for programs addressing high unmet
patient needs."
Precigen's J.P. Morgan presentation is available on the Company
website in the Events & Presentations section at
investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage
biopharmaceutical company advancing the next generation of gene and
cell therapies using precision technology to target the most urgent
and intractable diseases in our core therapeutic areas of
immuno-oncology, autoimmune disorders, and infectious diseases. Our
technologies enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated therapies toward clinical proof-of-concept
and commercialization. For more information about Precigen, visit
www.precigen.com or follow us on Twitter @Precigen,
LinkedIn or YouTube.
UltraCAR-T®
UltraCAR-T is a multigenic autologous CAR-T platform that utilizes
Precigen's advanced non-viral Sleeping Beauty system to
simultaneously express an antigen-specific CAR to specifically
target tumor cells, mbIL15 for enhanced in vivo expansion
and persistence, and a kill switch to conditionally eliminate CAR-T
cells for a potentially improved safety profile. Precigen has
advanced the UltraCAR-T platform to address the inhibitory tumor
microenvironment by incorporating a novel mechanism for intrinsic
checkpoint blockade without the need for complex and expensive gene
editing techniques. UltraCAR-T investigational therapies are
manufactured via Precigen's overnight manufacturing process using
the proprietary UltraPorator™ electroporation system
at the medical center and administered to patients only one day
following gene transfer. The overnight UltraCAR-T manufacturing
process does not use viral vectors and does not require ex
vivo activation and expansion of T cells, potentially
addressing major limitations of current T cell therapies.
AdenoVerse™ Immunotherapy
Precigen's AdenoVerse immunotherapy platform utilizes a library of
proprietary adenovectors for the efficient gene delivery of
therapeutic effectors, immunomodulators, and vaccine antigens
designed to modulate the immune system. Precigen's gorilla
adenovectors, part of the AdenoVerse library, have potentially
superior performance characteristics as compared to current
competition. AdenoVerse immunotherapies have been shown to generate
high-level and durable antigen-specific neutralizing antibodies and
effector T cell immune responses as well as an ability to boost
these antibody and T cell responses via repeat administration.
Superior performance characteristics and high yield manufacturing
of AdenoVerse vectors combined with UltraVector®
technology allows Precigen to engineer cutting-edge investigational
gene therapies to treat complex diseases.
UltraPorator™
The UltraPorator system is an exclusive device and proprietary
software solution for the scale-up of rapid and cost-effective
manufacturing of UltraCAR-T therapies and potentially represents a
major advancement over current electroporation devices by
significantly reducing the processing time and contamination risk.
The UltraPorator device is a high-throughput, semi-closed
electroporation system for modifying T cells using Precigen's
proprietary non-viral gene transfer technology. UltraPorator is
being utilized for clinical manufacturing of Precigen's
investigational UltraCAR-T therapies in compliance with current
good manufacturing practices.
ActoBiotics™
The ActoBiotics platform is precisely tailored for specific disease
modification with the potential for superior efficacy and safety
via local delivery directly to the relevant tissue. ActoBiotics are
targeted, microbe-based, and specifically designed agents that
express and locally deliver potential disease-modifying
therapeutics at disease sites including the intestine, the mouth
and the nasopharynx to treat a range of disorders.
Trademarks
Precigen, UltraCAR-T, AdenoVerse, UltraVector, UltraPorator,
ActoBiotics and Advancing Medicine with Precision are trademarks
of Precigen and/or its affiliates. Other names may be
trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release are
forward-looking statements. These forward-looking statements are
based upon the Company's current expectations and projections about
future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs and related milestones, the promise of
the Company's portfolio of therapies, and in particular its CAR-T
and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties, including the
possibility that the timeline for the Company's clinical trials
might be impacted by the COVID-19 pandemic, and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor
Contact:
Steven
Harasym
Vice President,
Investor Relations
Tel: +1 (301)
556-9850
investors@precigen.com
|
Media
Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn
Silver
Lazar-FINN
Partners
glenn.silver@finnpartners.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-provides-pipeline-and-corporate-updates-at-the-40th-annual-jp-morgan-healthcare-conference-301459811.html
SOURCE Precigen, Inc.